RareCyte, Inc. signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).

RareCyte, Inc. signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).
According to the news:

The specific goals of the CRADA include the detection, characterization, single cell retrieval, and analysis of rare circulating immune cells, such as natural killer T (NKT) cells and antigen-specific conventional T cells, and CTCs derived from preclinical and clinical studies conducted by the NCI and the development of assays showing response to immunotherapy and the extent of cancer progression.

Eric Kaldjian, MD, chief medical officer of RareCyte and CRADA collaborator principal investigator commented:

With advances in cancer immunotherapy, a significant challenge remains in identifying immunologic responses that correlate with beneficial clinical outcomes. The ability to characterize the immune response is an important aspect of personalized approaches for patients undergoing cancer immunotherapy. We believe that RareCyte’s technology makes this possible.

Click here to view the full press release.

assays cancer clinical studies immunotherapy Biotech Investing